R
Raveen Rathnasinghe
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 42
Citations - 2394
Raveen Rathnasinghe is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & Virus. The author has an hindex of 12, co-authored 30 publications receiving 1037 citations. Previous affiliations of Raveen Rathnasinghe include Mount Sinai Health System.
Papers
More filters
Journal ArticleDOI
Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera
Raveen Rathnasinghe,Sonia Jangra,Chengjin Ye,Anastasija Cupic,Gagandeep Singh,Carles Martínez-Romero,Lubbertus C. F. Mulder,Thomas Kehrer,Soner Yildiz,Angela Choi,Stephen T. Yeung,Ignacio Mena,Virginia L. Gillespie,Jana De Vrieze,Sadaf Aslam,Daniel Stadlbauer,David A. Meekins,Chester McDowell,Velmurugan Balaraman,Michael J. Corley,Jürgen A. Richt,Bruno G. De Geest,Lisa Miorin,Giulio Kleiner,Miti Saksena,Komal Srivastava,C. Gleason,Maria Bermudez-Gonzalez,K. Beach,Kayla T. Russo,L. Sominsky,E Ferreri,Rachel Chernet,Lily Q. Eaker,A. Salimbangon,Denise Jurczyszak,Hala Alshammary,W. Mendez,Angela Amoako,Shelcie Fabre,Mahmoud Awawda,A. Shin,Florian Krammer,Luis Martinez-Sobrido,Viviana Simon,Adolfo García-Sastre,Michael Schotsaert +46 more
TL;DR: In this paper , the authors showed that serial passaging of USA-WA1/2020 strain in mouse lungs results in "mouse-adapted" SARS-CoV-2 (MA-SARS CoV2) with mutations in S, M, and N genes, and a twelve-nucleotide insertion in the S gene.
Posted ContentDOI
Topoisomerase 1 inhibition therapy protects against SARS-CoV-2-induced inflammation and death in animal models.
Jessica Sook Yuin Ho,Bobo Wing-Yee Mok,Laura Campisi,Tristan X. Jordan,Soner Yildiz,Natasha N. Gaudreault,David A. Meekins,Sabarish V. Indran,Igor Morozov,Jessie D. Trujillo,Yesai Fstkchyan,Raveen Rathnasinghe,Zeyu Zhu,Simin Zheng,Nan Zhao,Kris M. White,Helen Ray-Jones,Valeriya Malysheva,Michiel J. Thiecke,Siu-Ying Lau,Honglian Liu,Anna Junxia Zhang,Andrew Chak-Yiu Lee,Wen-Chun Liu,Teresa Aydillo,Betsaida Salom Melo,Ernesto Guccione,Robert Sebra,Elaine Shum,Jan Bakker,David A. Kaufman,Andre L. Moreira,Mariano Carossino,Udeni B. R. Balasuriya,Minji Byun,Randy A. Albrecht,Michael Schotsaert,Adolfo García-Sastre,Sumit K. Chanda,Anand D. Jeyasekharan,Benjamin R. tenOever,Mikhail Spivakov,Sven Heinz,Honglin Chen,Christopher Benner,Juergen A. Richt,Ivan Marazzi +46 more
TL;DR: Therapeutic treatment with two doses of Topotecan (TPT), a FDA-approved Top1 inhibitor, suppresses infection-induced inflammation in hamsters and support the potential of Top1 inhibition as an effective host-directed therapy against severe SARS-CoV-2 infection.
Posted ContentDOI
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.
Roger Le Grand,Pauline Maisonnasse,Yoann Aldon,Aurélien Marc,Romain Marlin,Nathalie Dereuddre-Bosquet,Natalia Kuzmina,Alec W. Freyn,Jonne L. Snitselaar,Antonio Gonçalves,Tom G. Caniels,Judith A. Burger,Meliawati Poniman,Virginie Chesnais,Ségolène Diry,Anton Iershov,Adam J. Ronk,Sonia Jangra,Raveen Rathnasinghe,Philip J. M. Brouwer,Tom P. L. Bijl,Jelle van Schooten,Mitch Brinkkemper,Hejun Liu,Meng Yuan,Chad E. Mire,Mariëlle J. van Breemen,Vanessa Contreras,Thibaut Naninck,Julien Lemaitre,Nidhal Kahlaoui,Francis Relouzat,Catherine Chapon,Raphael Ho Tsong Fang,Charlene McDanal,Mary Osei-Twum,Natalie St-Amant,Luc Gagnon,David C. Montefiori,Ian A. Wilson,Eric Ginoux,Godelieve J. de Bree,Adolfo García-Sastre,Michael Schotsaert,Lynda Coughlan,Alexander Bukreyev,Sylvie van der Werf,Jeremie Guedj,Rogier W. Sanders,Marit van Gils +49 more
TL;DR: In this article, the authors evaluated the prophylactic and therapeutic effect of COVA1-18 in vivo, a neutralizing antibody isolated from a convalescent patient and highly potent against the B.1.7.
Posted ContentDOI
SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage
Alba Escalera,Ana S. Gonzalez-Reiche,Sadaf Aslam,Ignacio Mena,Rebecca L. Pearl,Manon Laporte,Andrea Fossati,Raveen Rathnasinghe,Hala Alshammary,Adriana van de Guchte,Mehdi Bouhaddou,Thomas Kehrer,Lorena Zuliani-Alvarez,David A. Meekins,Velmurugan Balaraman,Chester McDowell,Juergen A. Richt,Goran Bajic,Emilia Mia Sordillo,Nevan J. Krogan,Viviana Simon,Randy A. Albrecht,Harm van Bakel,Adolfo García-Sastre,Teresa Aydillo +24 more
TL;DR: In this article, the role of arising S polymorphisms in vitro and in vivo to understand the emergence of SARS-CoV-2 variants was investigated, and it was shown that the S:655Y is an important adaptative mutation that increases viral cell entry, transmission, and host susceptibility.
Posted ContentDOI
The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters
Lisa Miorin,Chad E. Mire,Shahin Ranjbar,Adam J. Hume,Jessie Huang,Nicholas A. Crossland,Kris M. White,Manon Laporte,Thomas Kehrer,Viraga Haridas,Elena Moreno,Aya Nambu,Sonia Jangra,Anastasija Cupic,Marion Dejosez,Kristine A Abo,Anna Tseng,Rhiannon B. Werder,Raveen Rathnasinghe,Tinaye Mutetwa,Irene Ramos,Julio Sainz de Aja,Carolina Garcia de Alba Rivas,Michael Schotsaert,Ronald B. Corley,James V. Falvo,Ana Fernandez-Sesma,Carla F. Kim,Jean-Francois Rossignol,Andrew J. Wilson,Thomas P. Zwaka,Darrell N. Kotton,Elke Mühlberger,Adolfo García-Sastre,Anne E. Goldfeld +34 more
TL;DR: It is shown that the oral FDA-approved drug nitazoxanide (NTZ) significantly inhibits SARS-CoV-2 viral replication and infection in different primate and human cell models including stem cell-derived human alveolar epithelial type 2 cells and it synergizes with remdesivir.